Literature DB >> 2905241

A comparison of roxatidine acetate 150 mg once daily and 75 mg twice daily in gastric ulcer healing.

W Rösch1.   

Abstract

In 363 outpatients with endoscopically confirmed gastric ulcers the efficacy and safety of roxatidine acetate 150 mg at night was compared to 75 mg twice daily. After 8 weeks' treatment substantial reductions in gastric ulcer diameter were obtained in addition to healing rates of 83.7 and 86% for the twice daily and night-time dosing, respectively. Daily reductions in day and night-time epigastric pain were obtained with no significant differences between treatment groups for pain scores or antacid tablet consumption. Furthermore, cigarette smoking did not influence the healing rates produced by either treatment schedule. 26 patients reported 32 adverse reactions and 5 patients discontinued treatment because of side effects, although only 1 of these was a severe reaction. The present data suggest that a single night-time dose of roxatidine acetate 150 mg is as safe and effective as the twice daily dose regimen for the management of acute gastric ulceration.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2905241     DOI: 10.2165/00003495-198800353-00022

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  8 in total

1.  A comparison of roxatidine acetate 150 mg once daily and 75 mg twice daily in duodenal ulcer healing.

Authors:  E Hentschel; K Schütze
Journal:  Drugs       Date:  1988       Impact factor: 9.546

2.  A comparison of roxatidine acetate and ranitidine in duodenal ulcer healing.

Authors:  W Hüttemann
Journal:  Drugs       Date:  1988       Impact factor: 9.546

3.  Cimetidine once daily.

Authors:  M Delattre; B Dickson
Journal:  Lancet       Date:  1984-03-17       Impact factor: 79.321

4.  24 hour intragastric acidity and single night-time dose of three H-2-blockers.

Authors:  H G Dammann; P Müller; B Simon
Journal:  Lancet       Date:  1983-11-05       Impact factor: 79.321

5.  Nocturnal doses of H2 receptor antagonists for duodenal ulcer.

Authors:  C W Howden; D B Jones; R H Hunt
Journal:  Lancet       Date:  1985-03-16       Impact factor: 79.321

6.  24 hour intragastric acidity during maintenance treatment with ranitidine.

Authors:  I A Santana; B K Sharma; R E Pounder; E C Wood; S Masters; M Talbot
Journal:  Br Med J (Clin Res Ed)       Date:  1984-11-24

7.  Single nocturnal dose of an H2 receptor antagonist for the treatment of duodenal ulcer.

Authors:  T Gledhill; O M Howard; M Buck; A Paul; R H Hunt
Journal:  Gut       Date:  1983-10       Impact factor: 23.059

Review 8.  Famotidine. Pharmacodynamic and pharmacokinetic properties and a preliminary review of its therapeutic use in peptic ulcer disease and Zollinger-Ellison syndrome.

Authors:  D M Campoli-Richards; S P Clissold
Journal:  Drugs       Date:  1986-09       Impact factor: 9.546

  8 in total
  2 in total

1.  Roxatidine acetate in the long term maintenance of gastric ulcers.

Authors:  G Börsch
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 2.  Roxatidine acetate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic potential in peptic ulcer disease and related disorders.

Authors:  D Murdoch; D McTavish
Journal:  Drugs       Date:  1991-08       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.